LAILA MADHANI: Open Payments
NPI 1578957254 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,375 in 54 payments from 20 companies in 2025. Trend: 2023 $0 · 2024 $405 · 2025 $1,375
Food & beverage: $1,375
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 6 | $233 |
| AstraZeneca Pharmaceuticals LP | 9 | $152 |
| Recor Medical Inc | 4 | $135 |
| Otsuka America Pharmaceutical, Inc. | 4 | $116 |
| Novo Nordisk Inc | 4 | $107 |
| Mallinckrodt Hospital Products Inc. | 4 | $91 |
| Calliditas Therapeutics US Inc. | 4 | $90 |
| Ardelyx, Inc. | 3 | $72 |
| OPKO Pharmaceuticals, LLC | 3 | $60 |
| Alexion Pharmaceuticals, Inc. | 2 | $50 |
Products named: KRYSTEXXA, FARXIGA, Paradise Ultrasound Renal Denervation System, JYNARQUE, Ozempic, ACTHAR, TARPEYO, IBSRELA.
Industry payments across TX — which companies pay providers there.
